News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) India Patent Case Postponed to August 22



7/9/2012 7:04:38 AM

The final judgment from the eagerly-anticipated court case that involves Novartis' legal challenge against India's patent laws has been put back once again. The Swiss major's long-running case against the Government of India centres around the country's patent law, notably Section 3(d), which states that a modification of a known chemical composition is non-patentable. Novartis' legal action stems from an attempt to obtain an Indian patent on Gleevec/Glivec (imatinib mesylate), its drug for chronic myeloid leukaemia and other cancers, which was denied by India's Patent Office in 2006.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES